Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000499572 | SCV000596559 | likely pathogenic | PPARG-related familial partial lipodystrophy | 2016-08-08 | criteria provided, single submitter | clinical testing | |
Broad Center for Mendelian Genomics, |
RCV000499572 | SCV001423110 | likely pathogenic | PPARG-related familial partial lipodystrophy | 2020-01-22 | criteria provided, single submitter | curation | The p.Arg194Gln variant in PPARG has been reported in 2 individuals suspected to have Familial Partial Lipodystrophy (PMID: 27749844), and has also been reported likely pathogenic in ClinVar (Variation ID: 436397). This variant was absent from large population studies. In vitro functional studies provide some evidence that the p.Arg194Gln variant may eliminate protein function (PMID: 27749844). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. One additional variant, causing a different amino acid change at the same position, p.Arg194Trp, has been reported in association with disease in the literature, slightly supporting that a change at this position may not be tolerated (PMID: 17299075; DOI: 10.1530/endoabs.41.GP59). In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PS3, PM2, PP3, PM5_Supporting (Richards 2015). |